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Abstract
Mevalonic aciduria (MVA) and hyperimmunoglobulinemia D syndrome (HIDS) represent the two
ends of a clinical spectrum of disease caused by deficiency of mevalonate kinase (MVK), the first
committed enzyme of cholesterol biosynthesis. At least 30 patients with MVA and 180 patients
with HIDS have been reported worldwide. MVA is characterized by psychomotor retardation,
failure to thrive, progressive cerebellar ataxia, dysmorphic features, progressive visual impairment
and recurrent febrile crises. The febrile episodes are commonly accompanied by
hepatosplenomegaly, lymphadenopathy, abdominal symptoms, arthralgia and skin rashes. Life
expectancy is often compromised. In HIDS, only febrile attacks are present, but a subgroup of
patients may also develop neurological abnormalities of varying degree such as mental retardation,
ataxia, ocular symptoms and epilepsy. A reduced activity of MVK and pathogenic mutations in the
MVK gene have been demonstrated as the common genetic basis in both disorders. In MVA, the
diagnosis is established by detection of highly elevated levels of mevalonic acid excreted in urine.
Increased levels of immunoglobulin D (IgD) and, in most patients of immunoglobulin A (IgA), in
combination with enhanced excretion of mevalonic acid provide strong evidence for HIDS. The
diagnosis is confirmed by low activity of mevalonate kinase or by demonstration of disease-causing
mutations. Genetic counseling shoul d  b e  o f f e r e d  t o  f a m i l i e s  a t  risk. There is no established
successful treatment for MVA. Simvastatin, an inhibitor of HMG-CoA reductase, and anakinra have
been shown to have beneficial effect in HIDS.
Disease name and synonyms
Mevalonic aciduria (MVA, OMIM 251170).
Hyperimmunoglobulinemia D and periodic fever syn-
drome; Periodic fever, Dutch type (HIDS, OMIM
260920).
Definition and diagnostic criteria
MVA is an autosomal recessively inherited disorder caused
by deficiency of mevalonate kinase (MVK; E.C. 2.7.1.36;
ATP:(R)-mevalonate 5-phosphotransferase) and identi-
fied as the first defect in cholesterol biosynthesis (Figure
1) by Hoffmann et al. in 1986 [1]. Mutations in the MVK
gene and reduced activity of MVK have been identified as
underlying cause of both MVA and HIDS syndrome.
MVA is caused by homozygosity or compound heterozy-
gosity for disease-causing mutations in the MVK  gene,
which has been localized to chromosome 12q24 [2]. MVA
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is biochemically characterized by accumulation of meval-
onic acid and mevalonolactone.
The diagnosis of MVA should be suspected in patients
with mild dysmorphic features, progressive cerebellar
ataxia, psychomotor retardation, failure to thrive, hepat-
osplenomegaly and recurrent febrile episodes. Uveitis,
retinitis pigmentosa and cataracts, as well as myopathy
may develop in childhood and adolescence.
HIDS is clinically characterized by recurrent fever epi-
sodes starting in infancy and associated with lymphaden-
opathy, arthralgia, gastrointestinal problems and skin
rashes.
A subgroup of HIDS patients may also develop neurolog-
ical abnormalities of varying degree, such as mental retar-
dation, ataxia, ocular symptoms and epilepsy, a finding
that confirms the existence of a continuous spectrum
between MVA and HIDS [3].
The diagnosis is established by the detection of elevated
excretion of mevalonic acid in urine (MVA) or increased
immunoglobulins (Ig) D and A in combination with ele-
vated excretion of mevalonic acid (HIDS). The diagnosis
is confirmed by demonstration of deficient MVK enzyme
activity or by identification of two disease-causing muta-
tions in the MVK gene.
Differential diagnosis
The constellation of congenital malformations, hepat-
osplenomegaly, cholestatic liver disease, lymphadenopa-
thy, anemia, severe failure to thrive and developmental
retardation, which is found in severely affected MVA
patients might suggest chromosomal aberrations or con-
genital infections. When hematological abnormalities
such as anemia, leukocytosis, thrombocytopenia and
abnormal blood cell forms predominate, myelodysplastic
syndromes may be suspected. Moderately affected MVA
patients may be classified among those with psychomotor
retardation, myopathy and ataxia.
Recurrent crises from infancy of fever, diarrhea and muco-
cutaneous manifestations might suggest infectious or
autoimmune disease [4]. The development of uveitis in
some patients parallels that seen in juvenile rheumatoid
arthritis [5]. If developmental delay and neurological
symptoms are neither present nor prominent, the differ-
ential diagnosis is likely to focus within the group of auto-
inflammatory disorders. This group consists of other
inherited syndromes: familial Mediterranean fever (FMF);
TNF receptor-associated periodic syndrome (TRAPS);
familial cold autoinflammatory syndrome/Muckle-Wells
syndrome/chronic infantile neurological cutaneous and
articular syndrome (FCAS/MWS/CINCA) and periodic
fever, aphthous ulcers, pharyngitis, adenitis (PFAPA).
Epidemiology
MVA is a rare disease. So far, approximately 30 patients
have been reported. HIDS seems to be more common. In
2001, the number of reported HIDS patients was about
180 [6] and more patients have been identified since.
Etiology
For MVA, seven mutations have been identified in 10 out
of 20 known patients [7]. Most of these mutations cluster
in the C-terminal region of the protein.
Most patients with HIDS are compound heterozygotes for
missense mutations in the MVK  gene. One mutation,
V337I, is present in more than 80% of patients [8]. This
mutation primarily affects maturation (folding) of the
protein resulting in temperature-sensitive expression of
MVK in vivo [9]. In HIDS patients, MVK may have a resid-
ual activity of 5%–15%. In contrast, no residual activity is
present in MVA patients [4].
Clinical description
Mevalonic aciduria
MVA shows considerable clinical heterogeneity. Severely
affected patients present from birth with congenital mal-
formations such as microcephaly, dolichocephaly and
wide irregular fontanels, as well as low set and posteriorly
rotated ears, downslanted palpebral fissures, blue sclerae,
and central cataracts (Figure 2). Cholestatic liver disease
[10] may be present, and patients may die from recurrent
septicemia [11]. Stillbirths with skeletal malformations
have been observed in affected families, possibly resulting
from the same genetic defect. Cardinal manifestations
Pathway of cholesterol biosynthesis, showing the defect in  mevalonate kinase (MVK) deficiency Figure 1
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from late infancy include mild to severe psychomotor
retardation, recurrent crises (fever, vomiting and
diarrhea), failure to thrive, hypotonia and myopathy.
Sometimes hematological abnormalities predominate
with normocytic hypoplastic anemia, leukocytosis,
thrombocytopenia and abnormal blood cell forms [10],
leading to misdiagnoses of congenital infection or myelo-
dysplastic syndromes.
After preschool age, short stature, ataxia due to a progres-
sive cerebellar atrophy and ocular involvement with uvei-
tis, cataracts and tapetoretinal degeneration become
predominant findings, and can be the major manifesta-
tions in milder cases [3-5,12].
Most patients suffer from frequent crises characterized by
fever, vomiting and diarrhea. These episodes appear to be
noninfectious in origin, and are often accompanied by
arthralgia, subcutaneous edema and a morbilliform rash.
Two patients developed uveitis, which worsened during
crises. In childhood, episodes occur as often as 25 times
per year, lasting in average 4 to 5 days. Laboratory investi-
gations reveal elevated acute phase reactants (erythrocyte
sedimentation rate, C-reactive protein, leukocytosis) and
elevated immunoglobulins, including IgA, IgE and espe-
cially IgD. Anemia, elevations of creatine kinase (CK) and
transaminases are present in the more severely affected
patients, and worsen during crises. Over the years, the
severity and the frequency of the attacks decline.
Hyperimmunoglobulinemia D syndrome
In HIDS, the clinical picture is dominated by recurrent
febrile attacks that usually start before the end of the first
year of life [13]. The fever lasts 4 to 6 days and can be pro-
voked by vaccination, minor trauma, surgery or stress. It is
usually associated with abdominal pain, vomiting,
diarrhea and cervical lymphadenopathy. Other common
symptoms include hepatosplenomegaly, headache,
arthralgia and rashes. Occasionally, patients present with
oral and vaginal aphthous ulcers. After the attack, the
patients are free of symptoms, although skin and joint
symptoms disappear slowly [6]. Most patients display nei-
ther malformations nor neurological abnormalities. How-
ever, a subgroup of adult patients also develop
neurological abnormalities of varying degree, such as
mental retardation, ataxia, ocular symptoms and epilepsy,
reflecting the existence of a continuous spectrum between
MVA and HIDS [3].
Diagnostic methods
Generally, the metabolic abnormalities seen in MVA are
not those suggestive of an inherited organic aciduria.
There is no episodic metabolic decompensation, hypogly-
cemia, metabolic acidosis, ketosis or hyperammonemia.
The key for diagnosis is the elevated level of mevalonic
acid in the urine, plasma and cerebrospinal fluid, which
can be detected through organic acid analysis [14]. How-
ever, in patients with a mild form of MVA and especially
in HIDS patients, elevations measured by routine gas
chromatography/mass spectrometry may only be found
during febrile attacks. The sensitivity of general organic
acid analysis is inadequate for recognizing the very low
concentrations of mevalonic acid present in control urine.
Even moderate, but definitely pathological, elevations can
remain below the detection limit [14], and must be veri-
fied by isotope dilution mass spectrometry [15]. As the
absolute level of mevalonic acid is always elevated in
patients with MVK deficiency, samples from patients with
a suspected MVA deficiency should undergo a sensitive
measurement of mevalonic acid by stable isotope dilution
analysis to detect even slight abnormalities. The diagnosis
of MVA should be confirmed by mutational analysis or by
a radiometric assay of MVK in white blood cells or cul-
tured fibroblasts [16,17]. Urinary excretion of leukotriene
A patient with mevalonic aciduria at the age of 21 months  displaying the characteristic facial dysmorphism Figure 2
A patient with mevalonic aciduria at the age of 21 months 
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E4 is elevated in most patients, with a positive linear cor-
relation with increased mevalonic acid excretion [18].
HIDS is diagnosed on the basis of characteristic clinical
findings and continuously high IgD values (more than
100 IU/ml). However, IgD may be normal in patients
under three years of age [19]. Consistently normal IgD
levels were found in two patients with typical clinical find-
ings and genotype for the syndrome [3,20]. More than
80% of patients have, in addition, high IgA levels [19,21].
During febrile episodes, urinary mevalonate concentra-
tions were found to be significantly elevated in patients
with at least one mutation in the MVK gene, but slight ele-
vations were also detected between the fever attacks [22].
Therefore, specific sensitive determination of mevalonic
acid, mutational analysis and determination of enzyme
activity should be performed in all cases with suggestive
clinical symptoms and normal IgD levels.
Genetic counseling and prenatal diagnosis
Genetic counseling should be offered to families at risk of
MVA. As MVA is an autosomal recessive disorder, the risk
for future pregnancies is 25% for families who already
have a child with MVA.
Prenatal diagnosis of an affected fetus is possible by stable
isotope-dilution gas chromatography/mass spectrometry,
by determination of MVK activity in cultured amniocytes
and biopsied chorionic villus [1,12,14,17], and by muta-
tional analysis in informative families. In affected preg-
nancies, elevated levels of mevalonic acid have been
detected in maternal urine [1,12,14]. Significant eleva-
tions of mevalonic acid have been detected in autopsied
tissues (including lymph nodes, adrenals, ovaries, spleen,
liver and brain) from an affected fetus, [14].
Prenatal diagnosis is usually not considered to be appro-
priate for HIDS.
Management including treatment
There is no established therapeutic regime for patients
with MVA. Dietary supplementation of cholesterol may
reduce the frequency and severity of febrile attacks in
some mildly affected patients, but may further compro-
mise more severely affected patients [4]. An experimental
trial with lovastatin in two patients with MVA resulted in
clinical decompensation manifested by fever, acute myo-
pathic changes, highly elevated creatine kinase activity,
and worsened ataxia, diarrhea and vomiting. Intervention
with corticosteroids (prednisone 2 mg/kg per day) was
highly beneficial during clinical crises, with resolution of
the crises within 24 hours. Additional long-term adminis-
tration of ubiquinone-50, together with vitamin C and
vitamin E, appeared to stabilize the clinical course and
improve somatic and psychomotor development. The
rationale is to correct the ubiquinone-50 deficiency and to
increase the level of free radical scavengers [23].
Treatment of HIDS is difficult and largely supportive. Var-
ious standard anti-inflammatory drugs (including colchi-
cine, non steroidal anti-inflammatory drugs (NSAIDs),
steroids and thalidomide) have failed to suppress the
attacks. Despite the severe side effects of 3'-hydroxy-3'-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhib-
itors in patients with classic MVA, a recently completed
study showed a reduced excretion of mevalonic acid in all
patients, a decreased number of febrile days in most of the
patients with HIDS, and no side effects during simvastatin
treatment [24]. Similarly, a beneficial effect of anakinra (a
recombinant interleukin-1 receptor antagonist) was
described in one patient [25].
Prognosis
In early-onset multisystemic MVA, the prognosis is poor,
with about half of patients succumbing in infancy or early
childhood [4]. Mildly affected patients will develop short
stature, progressive myopathy and, possibly, visual
impairment due to uveitis, cataracts and tapetoretinal
degeneration. The severity and frequency of the febrile
attacks decline with age. In general, HIDS is considered to
be a relatively benign condition. However, life expectancy
may be reduced in some patients due to severe infections
or the development of renal amyloidosis [26].
Unresolved questions
It is still not known how the deficiency of MVK is related
to the inflammatory periodic fever syndrome. Elevations
of IgD, IgA and urinary leukotriene E4 excretion are prob-
ably secondary to stimulation of the immune system [27].
Further information
http://www.hids.net: A comprehensive website for clini-
cians, scientists, patients and their carers. The site is main-
tained by the HIDS research group at the Department of
General Internal Medicine, Radboud University Medical
Center, Nijmegen, The Netherlands.
Note
Figure 2 is reproduced with permission from Haas et al.
2001, © Georg Thieme Verlag KG
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